Vol. 8, 2023
Pharmaceutical Sciences
HEALTH EDUCATION OF THE POPULATION ABOUT THE PREVENTION POSSIBILITIES OF HPV INFECTION
Milica Stanojević, Jasmina Jovanović Mirković, Nataša Rančić, Christos Alexopoulos, Violeta Ilić Todorović, Svetlana Čapaković
Pages: 45-49
DOI: 10.37392/RapProc.2023.10
Abstract | References | Full Text (PDF)
Introduction.
Human papillomaviruses (Human Papillomavirus-HPV) are DNA viruses,
belonging to the family Papillomaviridae, genus Papillomavirus. It is estimated
that at least 80%-100% of people between the ages of 18-25 come into contact
with this virus during sexual contact, while only about 30% of people develop
symptoms of infection. Chronic HPV infection increases the risk of cervical
cancer by 65 times, and in the case of oncogenic “high-risk” types by 130 times
(HPV 16, HPV 18, HPV 31, HPV 35), namely cancer of the cervix, vulva and vagina
in women, genital organs in men, as well as throat and anus cancer in both
sexes. CIN within the framework of HPV infection and pathogenesis can be viewed
as a productive infection (replicative) that is most often transient and
spontaneously regresses (viral phase) and transformational with the development
of dysplasia in a smaller number of HPV-infection-related lesions (neoplastic
phase). As a preventive measure, there are vaccines against HPV (Gardasil,
Gardasil 9 and Cervarix), which are not mandatory according to the vaccination
calendar and contribute to preventing the development of HPV infection, and are
particularly effective in the fight against HPV types 16 and 18, which in most
cases cause cervical cancer. The aim of this work is to compare
the obtained data on the optional Gardasil 9 vaccination carried out on the
territory of Pomoravlje and Pcinja districts in Serbia in the year 2022.
Methodology of the research work. A descriptive study was
applied in this research paper. A special database was created for data entry
in the time interval in year 2022. The data were calculated in the SPSS
Statistics 20 software package. The data were presented graphically.
Results and discussion.
Based on statistically processed data, it can be seen that in the south of
Serbia, out of the total number of distributed vaccines, which was 253 vaccines
for the Pcinja district, 86 vaccines (33.99%) were administered. Comparing the
data with the Pomoravlje district, there is a significant difference in the
number of distributed (769) and the number of applied vaccines (408), which
indicates that 53.06% of the distributed doses were applied for the period from
June 2022 by the end of the same year. Statistical processing of the obtained
data showed that the Gardasil 9 vaccination with the first and second doses of
the vaccine in persons older than 9 years and persons older than 15 years was
best carried out in 2022 in the Pomoravlje District in the cities of Jagodina
(59.41%) and Svilajnac (54.02%), and the smallest in the cities of Rekovac (35,
71%) and Cuprija (40.35%). While the least was implemented in the territory
of the Pcinja District in 2022 were in the cities: Bosilegrad, Presevo and
Trgoviste based on distributed doses and remaining unused vaccines (stock). The
highest response for optional free vaccination was in the cities of Surdulica
(66.675%), Bujanovac (39.58%) and Vranje (36.36%) in Pcinja District.
Conclusion.
By comparing the statistical data, it can be concluded that the success rate of
vaccination is significantly higher in central Serbia, in the territory of the
Pomoravlje District (53.06%), than in the south of Serbia, in the territory of
the Pcinja District (33.99%). Through educational lectures on vaccination
against HPVirus, children, adults and the entire population acquire positive
attitudes about prevention as one of the most effective methods in suppressing
and spreading the said disease.
-
M. Muller et al., “Chimeric papillomavirus-like particles,”
Virology
, vol. 234, no. 1, pp. 93 – 111, Jul. 1997.
DOI: 10.1006/viro.1997.8591
PMid: 9234950 -
E. M. Smith et al., “Human papillomavirus and risk of laryngeal cancer,”
Ann. Otol. Rhinol. Laryngol., vol. 109, no. 11, pp. 1069 – 1076,
Nov. 2000.
DOI: 10.1177/000348940010901114
PMid: 11090000 -
J. S. Smith et al., “Human papillomavirus type distribution in invasive
cervical cancer and high-grade cervical lesions: a meta-analysis update,”
Int. J. Cancer, vol. 121, no. 3, pp. 621 – 632, Aug. 2007.
DOI: 10.1002/ijc.22527
PMid: 17405118 -
D. M. Da Silva et al., “Physical interaction of human papillomavirus
virus-like particles with immune cells,” Int. Immunol., vol. 13,
no. 5, pp. 633 – 641, May 2001.
DOI: 10.1093/intimm/13.5.633
PMid: 11312251 -
F. X. Bosch et al., “Epidemiology and natural history of human
papillomavirus infections and type-specific implications in cervical
neoplasia,” Vaccine, vol. 26, suppl. 10, pp. K1 – K16, Aug. 2008.
DOI: 10.1016/j.vaccine.2008.05.064
PMid: 18847553 -
D. Dias et al., “Optimization and validation of a multiplexed luminex assay
to quantify antibodies to neutralizing epitopes on human papillomaviruses
6, 11, 16, and 18,” Clin. Diagn. Lab. Immunol., vol. 12, no. 8,
pp. 959 – 969, Aug. 2005.
DOI: 10.1128/CDLI.12.8.959-969.2005
PMid: 16085914
PMCid: PMC1182182 -
L. K. Borysiewicz et al., “A recombinant vaccinia virus encoding human
papillomavirus types 16
and 18, E6 and E7 proteins as immunotherapy
for cervical cancer,” Lancet, vol. 347, no. 9014,
pp. 1523 – 1527, Jun. 1996.
DOI: 10.1016/s0140-6736(96)90674-1
PMid: 8684105 -
D. M. Harper et al., “Efficacy of a bivalent L1 virus-like particle vaccine
in prevention of infection with human papillomavirus types 16 and 18 in
young women: a randomised controlled trial,” Lancet,
vol. 364, no. 9447, pp. 1757 – 1765, Nov. 2004.
DOI: 10.1016/S0140-6736(04)17398-4
PMid: 15541448 -
G. M. Clifford, J. S. Smith, M. Plummer, N. Munoz, S. Franceschi, “Human
papillomavirus types in invasive cervical cancer worldwide: a
meta-analysis,” Br. J. Cancer, vol. 88, no. 1, pp. 63 – 73, Jan.
2003.
DOI: 10.1038/sj.bjc.6600688
PMid: 12556961
PMCid: PMC2376782 -
A. T. Lorincz et al., “Human papillomavirus infection of the cervix:
relative risk associations of
15 common anogenital types,” Obstet. GynecoI.,
vol. 79, no. 3, pp. 328 – 337, Mar. 1992.
DOI: 10.1097/00006250-199203000-00002
PMid: 1310805 -
J. R. Daling et al., “A population-based study of squamous cell vaginal
cancer: HPV and cofactors,” Gynecol. Oncol., vol. 84, no. 2, pp.
263 – 270,
Feb. 2002.
DOI: 10.1006/gyno.2001.6502
PMid: 11812085 -
T. C. Wright, T. V. Ellerbrock, M. A. Chiasson, N. Van Devanter, X. W. Sun,
“Cervical intraepithelial neoplasia in women infected with human
immunodeficiency virus: Prevalence, risk factors, and validity of
Papanicolaou smears,” Obstet. Gynecol., vol. 84, no. 4, pp. 591 –
597, Oct. 1994.
Retrieved from: https://pubmed.ncbi.nlm.nih.gov/8090399/
Retrieved on: May 20, 2023 -
K. B. Michels, H. Z. Hausen, “HPV vaccine for all,” Lancet, vol.
374, no. 9686, pp. 268 – 270, Jul. 2009.
DOI: 10.1016/S0140-6736(09)61247-2
PMid: 19586657 -
L. L. Villa et al., “Immunologic responses following administration of a
vaccine targeting human papillomavirus Types 6, 11, 16, and 18,”
Vaccine
, vol. 24, no. 27-28, pp. 5571 – 5583, Jul. 2006.
DOI: 10.1016/j.vaccine.2006.04.068
PMid: 16753240 -
K. Schafer et al., “Immune response to human papillomavirus 16 L1E7
chimeric virus-like particles: induction of cytotoxic T cells and specific
tumor protection,” Int. J. Cancer, vol. 81, no. 6, pp. 881 – 888,
Nov. 1999.
Retrieved from: https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0215(19990611)81:6%3C881::AID-IJC8%3E3.0.CO;2-T
Retrieved on: May 20, 2023 -
P. Mayaud, D. Mabey, “Approaches to the control of sexually transmitted
infections in developing countries: old problems and modern challenges,”
Sex. Transm. Infect., vol. 80, no. 3, pp. 174 – 182, Jun. 2004.
DOI: 10.1136/sti.2002.004101
PMid: 15169997
PMCid: PMC1744836 -
R. E. Rupp, L. R. Stanberry, S. L. Rosenthal, “Vaccines for sexually
transmitted infections,” Pediatr. Ann. , vol. 34, no. 10,
pp. 818 – 824, Oct. 2005.
DOI: 10.3928/0090-4481-20051001-14
PMid: 16285635 -
S. H. Vermund et al., “High risk of human papillomavirus infection and
cervical squamous intraepithelial lesions among women with symptomatic
human immunodeficiency virus infection,” Am. J. Obstet. Gynecol.,
vol. 165, no. 2, pp. 392 – 400, Aug. 1991.
DOI: 10.1016/0002-9378(91)90101-v
PMid: 1651648 -
J. Berumen et al., “Asian-American variants of human papillomavirus 16 and
risk for cervical cancer: a case-control study,”
J. Natl. Cancer Inst.
, vol. 93, no. 17, pp. 1325 – 1330, Sep. 2001.
DOI: 10.1093/jnci/93.17.1325
PMid: 11535707 -
F. X. Bosch et al., “Prevalence of human papillomavirus in cervical cancer:
a worldwide perspective. International biological study on cervical cancer
(IBSCC) Study Group,” J. Natl. Cancer Inst., vol. 87, no. 11, pp.
796 – 802, Jun. 1995.
DOI: 10.1093/jnci/87.11.796
PMid: 7791229 -
A. N. Fiander et al., “Prime-boost vaccination strategy in women with
high-grade, noncervical anogenital intraepithelial neoplasia: clinical
results from a multicenter phase II trial,” Int. J. Gynecol. Cancer, vol. 16, no. 3, pp. 1075 – 1081, Jun.
2006.
DOI: 10.1111/j.1525-1438.2006.00598.x
PMid: 16803488 -
Y. Lu et al., “Immunological protection against HPV16 E7-expressing human
esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein
based vaccine in a Hu-PBL-SCID mouse model,” Biol. Pharm. Bull.,
vol. 30, no. 1, pp. 150 – 156, Jan. 2007.
DOI: 10.1248/bpb.30.150